Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Phase 2 Completed 26 enrolled Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center · collab Biogen · collab Genentech, Inc. · collab Massachusetts General Hospital · collab University of Rochester · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness of six cycles of concurrent fludarabine and rituximab in patients with mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma (MZL) or CD5-, CD10-, CD20+ low-grade B cell lymphomas.

Timeline

Start: 2003-12
Primary completion: 2008-10
Completion: 2012-01

Publications

Results Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, Joyce R, Takvorian RW, Fisher DC, Fisher RI, Liesveld J, Marquis D, Neuberg D, Freedman AS. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 Jun;145(6):741-8. doi: 10.1111/j.1365-2141.2009.07677.x. Epub 2009 Mar 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fludarabine	Small molecule	25 mg/m2	—
Subject	Rituximab	Monoclonal antibody	375 mg/m2	—

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Summary

Timeline

Publications

Drugs

Indications